ARCHIVES

NCI, IOM Called To Congress to Explain Divergent Positions On Minority Research

This article is from The Cancer Letter archive.

Vol. 25 No. 04 | January 29, 1999

Download PDF Visit The Full Archive

Related Articles

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012

ASCO Updates Clinical Recommendations On Use Of Bisphosphonates In Myeloma

May 25, 2007

Klausner To Serve As Advisor On Bioterrorism For NAS.

January 4, 2002

In Brief: Calabresi Named To President’s Cancer Panel; Mays Leaves NCI Technology Office For IVAX

May 5, 1995

Young Elected ACS President, Von eschenback Pres.-Elect.

November 9, 2001

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

July 25, 2014